Pulmonary hypertension market domestic drug rise the status of the original research drug is difficult to protect

1 November 2020, the State issued the third batch of centralized procurement of selected drugs officially implemented orders. The third batch of 55 varieties, the remarkable west of the non-slice 25mg, 50mg, 100mg specifications, Dapostin tablets 30mg, 60mg specifications. Dapostin tablets are inhibitors of serotonin reuptakes and are drugs for premature ejaculation in men. Sidna is a selective inhibitor of specific phosphate disgrysterase-5 (PDE-5) and is approved as a drug for the treatment of erectile dysfunction and pulmonary hypertension.

the current situation of pulmonary hypertensionPulmonary hypertension (PAH) is a malignant pulmonary vascular disease characterized by pulmonary pressure hypertension, which is an independent disease and called called vascular syndrome leading to right heart failure. This group is characterized by "blue lips" due to chronic hypoxia, which is considered a rare disease in developed countries such as Europe and the United States, with a incidence rate of about 15 per million to 50 per 1 million. Clinical studies in China show that the one-year survival rate of unfiltreated drug treatment in China is only 68%, and the one-year survival rate can be increased to 85.4% after receiving adequate targeted treatment.In 1995, after the listing of sodium prostatin in the United States, the curtain was drawn on PAH-targeted therapy. With advances in medicine, PAH's therapeutic drugs have evolved from calcium antagonists, prostatins and their structural analogotyps to endothosin-like antagonists, phosphatase-5 (PDE-5) inhibitors, bird glycoside cyclase (sGC) agonists, and cyclocetones.In 2019, global sales of Pulmonary Hypertension Research TOP8 therapeutic drugs were around $5 billion, down slightly from the previous year. This does not include anti-ED adaptation PDE-5 inhibitors and prostatin drugs. The global market for pulmonary hypertensive drugs is expected to be around $10 billion.Opsurnit (Maxitentan) accounted for 27.53 per cent, Adempas (Leosi) for 18.92 per cent and Uptravi (Slepag) for 16.9 per cent for pulmonary hyperbaric TOP8 treatments Tracleer (Posantan), Letairis (Amber Stein), Volibris (Arisantan), Revatip (Sidnaf) and Adcirca (Tadarafei) combined for 36.56 per cent.

China has included idiopathic pulmonary hypertension in the Rare DiseasesIn May 2018, the National Health and Wellness Commission and other five departments jointly formulated the "First Rare Diseases List", idiopathic pulmonary hypertension ranked among them. The International Forum on Pulmonary Hypertension, held in Guangzhou on December 7, 2019, pointed out that the incidence of PAH in China is 1%, and the China Charity Federation estimates that there are 12 million patients in China, of whom the patients with idiopathic pulmonary hypertension are conservatively estimated at 30,000-50,000, and are a vulnerable group in need of care.Guidelines for diagnosis and treatment of pulmonary hypertension in China 2018 indicate that pulmonary hypertension targeted drug therapy consists of five subses, namely, endothosin-subject antagonist Posantan, Anlisantan, masitentan; Prostatin IP-subjector astigtors are lypag; phosphate ddiszyme 5 inhibitors Sidnaf, tadalaf and valdanaphethin; synthetic prostaline similars such as bepretin, quercetin and ilo prostatin have all been listed in China.It is worth mentioning that in the pulmonary hypertension treatment market, Sidina non-tablets have oral convenience, cheap and cost-effective characteristics, compared with Valdina non, bee prostatin and other efficacy is significant; Therefore, sidna non-small dose tablets have become one of the main recommended drugs for the clinical treatment of pulmonary hypertension.On February 5, 2020, the State Drug Administration approved Pfizer's Sidina non-20mg specification for the treatment of pulmonary hypertension, the commodity name Revatio. The application was included in the Second Clinical List of New Drugs In Urgent Need of Overseas Medicines and qualified for priority review. The Pulmonary Hypertensive Drugs approved by the NMPA from 2018 to 2019 are 6 varieties, such as Spirepag tablets, Leosi tablets, machytentan tablets, Alesintan tablets, posantan dispersion tablets, andacid sidina tablets.

market for pulmonary hypertension in public hospitals in key provinces and citiesIn the first half of this year, under the influence of the epidemic, the number of out-patient clinics in public hospitals decreased, and in the first half of 2020 the market for terminal pulmonary hypertensive drugs in public hospitals declined from the same period in 2019, according to Minanet data.In recent years, in the domestic public hospital pulmonary hypertension standard targeted clinical drugs, the frequency of the use of TOP8 drugs are Posantan, Maxitentan, Anlisantan, Leosi, Slepag, Quprenier, Elo prostatin and Rivanto. Pfizer's Rivanto was approved in February 2020 and is not yet included in the statistics, so the top seven targeted drugs are already being used as PAH treatments in public hospitals. Of the 7 targeted drugs, all-oli (Posantan tablets) accounted for 28.27%, Aopu Shu (Maxitentan tablets) accounted for 23.93 percent, Andison tan tablets accounted for 16.00 percent, and Utobi (Slepag tablets) accounted for 11.91 percent.It's worth noting that The Anlison Tan tablet was approved for listing by the FDA in June 2007, and GlaxoSmithKline's Anlitham tablet was listed in China in 2010 under the commercial name Volhbris. Subsequently, the development of domestic generic drugs has made great progress.On July 31, 2018, The Anli shengtan tablets of Jiangsu Haussen Pharmaceuticals were approved in category 4 as imitations, as if they had passed a consistent evaluation. Subsequently, in May 2019, Zhengda Tianqing Pharmaceuticals' Anlisheng Tan tablets were approved and evaluated as imitation 4 categories, and in January 2020 Huahai Pharmaceuticals' Anli shengtan tablets were approved with imitation 4 categories and treated as reviews, which has now formed a competitive pattern of domestic and imported drugs 3-1.   In the first half of 2020, Howson Pharmaceuticals accounted for 44.48 percent, GlaxoSmithKline 35.33 percent, Huahai Pharmaceuticals 11.36 percent, and Zhengtianqing Pharmaceuticals 8.83 percent. In addition, many domestic enterprises on the development of Leosi, Slepag, Posentan and Maxi Tengtan is also hot.   According to the data of Minenet, the MaxiTentan tablets of Nanjing Zhengda Tianqing and Shanghai Xuantai Haimen Pharmaceuticals/Puji Biotech are under review, while the Anlitian tablets of three enterprises, Wuhan People's Welfare Andean Pharmaceuticals, Jiangsu Deyuan Pharmaceuticals and Jiangsu Jiayi Pharmaceuticals, are under review.

PDE-5 inhibitor dual-adaptive disorder entered the market   Currently, three of the original drugs for phosphate-5 inhibitors: Pfizer's Cedina, Lilly's Tadallaffei and Bayer's Valdi naf, have been approved for the domestic market. Clinical studies at home and abroad have confirmed that phosphate dylsterase 5 inhibitors are oral prescription drugs for the treatment of pulmonary hypertension and hypertension and hyper erectile dysfunction.   Sidnafony was approved by the FDA in 2005 to treat pulmonary hypertension, a trade called Revatio. On February 6, 2020, the State Drug Administration approved Pfizer's Sidina non-tablet (20 mg) for the treatment of pulmonary hypertension, the commodity name Rivanto.   Tadaraf has been approved by the FDA in May 2009 for the treatment of pulmonary hypertension (PAH), a joint market development by Lilly and Japan's new drug market. The global market for phosphate dylsterase 5 inhibitors will be $3.680 billion in 2019, showing a decline in competition for generics such as forests. (
meters intranet
)